Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (366 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 11 Sep 2024 – 20 Aug 2026, limited by Tata Nifty200 Alpha 30 Index Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Tata Nifty200 Alpha 30 Index Fund | Nifty 500 |
|---|---|---|
| 11 Sep 2024 | ₹100.00 | ₹100.00 |
| 09 Nov 2024 | ₹92.55 | ₹96.24 |
| 07 Jan 2025 | ₹92.09 | ₹94.94 |
| 07 Mar 2025 | ₹75.25 | ₹86.88 |
| 05 May 2025 | ₹83.26 | ₹94.32 |
| 03 Jul 2025 | ₹90.79 | ₹99.96 |
| 31 Aug 2025 | ₹85.87 | ₹95.46 |
| 29 Oct 2025 | ₹89.10 | ₹101.79 |
| 27 Dec 2025 | ₹87.49 | ₹101.06 |
| 24 Feb 2026 | ₹89.44 | ₹99.04 |
| 24 Apr 2026 | ₹87.91 | ₹95.92 |
| 22 Jun 2026 | ₹93.03 | ₹98.86 |
| 20 Aug 2026 | ₹92.75 | ₹99.92 |
| Metric | Tata · Regular NAV ₹8.96 Very High risk ★★☆☆☆ 1Y | Category median Index Funds · 366 funds |
|---|---|---|
| +4.32% | +5.43% | |
| — | +8.41% | |
| — | +8.95% | |
| — | +11.28% | |
| -3.81% | +7.40% | |
| +5.33% | — | |
| — | +11.37% | |
| — | +13.00% | |
| — | +11.07% | |
| Risk | ||
| 20.10% | 13.88% | |
| -0.11 | 0.25 | |
| -0.15 | 0.35 | |
| -29.71% | -16.66% | |
| Nifty 500 | — | |
| — | +0.30% | |
| — | 1.00 | |
| — | 101.3% | |
| — | 98.8% | |
| 1.36% | 0.96% | |
| ₹193.88Cr | ₹182.17Cr | |
| 0.25% | — | |
| None | — | |
| ₹100 | — | |
| ₹5.00K | — | |
| 170% | 35% | |
| Rakesh Prajapati | — | |
| 11 Sep 2024 | — | |
| 30 | — | |
| 46.6% | — | |
| 0.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.